Concise Prescribing Info
Listed in Dosage.
Dosage/Direction for Use
Adult: PO HTN Initial:1.25 mg/day, adjusted after 3-4 wk. Usual range: 2.5-5 mg/day, either alone or w/ other antihypertensives. Maintenance: 5 mg on alternate days. Oedema 5-10 mg/day, up to 20 mg/day if needed. Max: 80 mg/24 hr.
Should be taken with food. Take after breakfast.
Anuria; hepatic coma or pre-coma. Pregnancy.
Special Precautions
Pre-diabetes or DM; gout; SLE; hepatic and renal impairment; hypercholesterolaemia. Correct electrolyte disturbances prior to therapy. Risk of cross-sensitivity with sulfonamides, sulfonylureas, carbonic anhydrase inhibitors, thiazides and loop diuretics. Lactation.
Adverse Reactions
Chest pain, palpitation, necrotising angiitis, orthostatic hypotension, syncope, venous thrombosis, vertigo, volume depletion; depression, dizziness, chills, drowsiness, fatigue, restlessness, headache, lightheadedness; petechiae, photosensitivity, hypersensitivity reactions; gout attacks, electrolyte disturbances; abdominal bloating, diarrhoea, abdominal pain, anorexia, constipation, epigastric distress, nausea, xerostomia, pancreatitis, vomiting; impotence; aplastic anaemia, thrombocytopenia, haemoconcentration, leukopenia; cholestatic jaundice, hepatitis; joint pain, muscle cramps, weakness, neuropathy, paraesthesia; blurred vision; increased BUN, glucosuria.
Potentially Fatal: Stevens-Johnson syndrome, toxic epidermal necrolysis.
B D if used in gestational HTN.
Drug Interactions
Hypotensive and nephrotoxic effects of ACE inhibitors may be enhanced. Absorption may be reduced with bile acid sequestrants. Hyperglycaemic effect may be enhanced with diazoxide. May increase serum concentration and QTc-prolonging effect of dofetilide. May reduce lithium excretion. Hypotensive effect may be increased with alcohol.
CIMS Class
ATC Classification
C03BA08 - metolazone ; Belongs to the class of low-ceiling sulfonamide diuretics.
Disclaimer: This information is independently developed by CIMS based on metolazone from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2021 CIMS. All rights reserved. Powered by
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in